drugset / Trial / NCT00283699
A Pilot Study of Neurocysticercosis Treatment
Phase 3
Completed
178 enrolled
Columbia University
National Institute of Neurological Disorders and Stroke (NINDS) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine if treatment with albendazole improves the clinical outcome of neurocysticercosis infection and/or leads to the disappearance of cysts sooner when compared with symptomatic treatment.
Timeline
- Start
- 2001-02
- Primary completion
- 2005-02
- Completion
- 2005-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Albendazole | Small molecule | 15 mg/kg | Oral |
| Comparator | Albendazole | Small molecule | 800 mg | Oral |